SP100 and pancreatic adenocarcinoma: In summary, our comprehensive bioinformatics analysis of the SP100 family in PAAD sheds light on their crucial involvement in the onset and progression of this disease, thereby highlighting their potential as promising therapeutic targets and prognostic biomarkers for PAAD patients.